Department of Translational Research and of New Surgical and Medical Technologies, University of Pisa, Pisa - Italy.
Department of Clinical and Experimental Medicine, University of Pisa, Pisa - Italy.
Curr Neuropharmacol. 2023;21(4):951-987. doi: 10.2174/1570159X20666220217152617.
The use of exogenous melatonin (exo-MEL) as a sleep-promoting drug has been under extensive debate due to the lack of consistency of its described effects. In this study, we conduct a systematic and comprehensive review of the literature on the chronobiotic, sleep-inducing, and overall sleep-promoting properties of exo-MEL. To this aim, we first describe the possible pharmacological mechanisms involved in the sleep-promoting properties and then report the corresponding effects of exo-MEL administration on clinical outcomes in: a) healthy subjects, b) circadian rhythm sleep disorders, c) primary insomnia. Timing of administration and doses of exo-MEL received particular attention in this work. The exo-MEL pharmacological effects are hereby interpreted in view of changes in the physiological properties and rhythmicity of endogenous melatonin. Finally, we discuss some translational implications for the personalized use of exo-MEL in the clinical practice.
外源性褪黑素(exo-MEL)作为一种促进睡眠的药物,其描述效果缺乏一致性,因此一直存在广泛争议。在本研究中,我们对有关外源性褪黑素的生物钟、诱导睡眠和整体促进睡眠特性的文献进行了系统和全面的回顾。为此,我们首先描述了可能涉及促进睡眠特性的药理学机制,然后报告了外源性褪黑素给药对以下方面的临床结果的相应影响:a)健康受试者,b)昼夜节律睡眠障碍,c)原发性失眠。在这项工作中,特别关注了给药时间和外源性褪黑素的剂量。本文根据内源性褪黑素的生理特性和节律性变化来解释外源性褪黑素的药理学效应。最后,我们讨论了在临床实践中个性化使用外源性褪黑素的一些转化意义。